PanCryos

PanCryos is dedicated to developing a safe, scalable, and cost-efficient cell replacement therapy to improve quality of life of millions of people suffering from insulin-dependent diabetes. PanCryos has established a simplified and effective method to generate stem cell derived glucose responsive beta cells. This promising cell therapy, PanINSULA™, is in preclinical development and protected by IP licensed from Copenhagen University. PanCryos has started a capital raise to support the journey towards a phase I/IIa clinical trial in 2022 and the team is open to discuss partnerships that can promote a cell therapy solution in diabetes.

Contact name:

Jacqueline Ameri

Address:

Ole Maaløes Vej 3, c/o BioInnovation Institute, DK-2200 Copenhagen N, Denmark

Telephone:

+ 46 704 151 746

If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2019 Danskbiotek. All rights reserved.